SOLA Biosciences has announced new preclinical proof-of-concept data for SOL-257, an investigational gene therapy designed to address a core biological feature of ALS. The therapy targets misfolded TDP-43, a protein strongly linked to nerve cell damage in many people with the disease, with the goal of slowing or altering disease

Series Pre-A+ Financing completed with UTEC

SOLA presented in ALS ONE Conference